Abivax seeks to ease safety concerns with new data, boosting shares

The company released additional strong efficacy results, in a group of hard-to-treat patients

A micrograph of ulcerative colitis.Wikimedia Commons

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

LONDON — Abivax on Monday night disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks.

U.S.-listed shares of the French firm were up some 25% overnight into Tuesday morning.